ConvergeHEALTH by Deloitte Announces Landmark Collaboration With Moffitt …

Published April 2, 2014

ConvergeHEALTH by Deloitte Announces Landmark Collaboration with Moffitt …
NEW YORK, April 1, 2014 /PRNewswire/ — ConvergeHEALTH by Deloitte is announcing that M2Gen, a wholly-owned subsidiary of Moffitt Cancer Center, has joined its real-world evidence and analytics consortium to help transform cancer care around the use of …
Read more on PR Newswire (press release)

BUILDING ASSETS, REDUCING RISKS: Hazelden Publishing's Newest …
Schools that have implemented BUILDING ASSETS, REDUCING RISKS have reported dramatically reduced rates of class failure, improved graduation rates, reduction in the use of alcohol, tobacco, and other drug use, regardless of socio-economic … house in …
Read more on PR Newswire (press release)

Cytokinetics to Present at the 13th Annual Needham Healthcare Conference
Cytokinetics' lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is in Phase II clinical development for the potential treatment of heart failure. Amgen Inc. holds an exclusive license worldwide to develop and …
Read more on ACN Newswire (press release)

Find More Drug Treatment Programs In Nyc Information…